Please login to the form below

Not currently logged in
Email:
Password:

Rigel Pharmaceuticals

This page shows the latest Rigel Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... Rigel is also developing it for additional indications, including autoimmune

Latest news

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    Follows failure of fostamatinib disodium in rheumatoid arthritis trial. Rigel Pharmaceuticals plans to cut 30 jobs as part of a restructure of its research efforts following the failure of fostamatinib disodium ... Rigel said it expects to advance one of

  • AstraZeneca boosts R&D prospects with Pearl acquisition AstraZeneca boosts R&D prospects with Pearl acquisition

    Pharma and Omthera Pharmaceuticals. ... Other respiratory prospects for AZ include the JAK inhibitor R256 licensed last year from Rigel Pharmaceuticals in a deal that could be worth up to $100m.

  • Pfizer returns asthma drug to Rigel

    Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals. ... Pfizer is returning full rights to a clinical-stage inhaled asthma drug to Rigel Pharmaceuticals as part of a larger decision to move away from

  • AZ's phase III RA trial underway

    Fostamatinib was initially developed by Rigel Pharmaceuticals, with AZ purchasing rights to further develop and commercialise the drug in February 2010.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Salix Pharmaceuticals/ Valeant Pharmaceuticals. GI products. Corporate acquisition. 14, 500. Flexus Biosciences/ BMS. ... Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors -

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics